ClindabacTM Capsule and: Clindamycin has been shown to be effective in the treatment of the following infections when caused by susceptible anaerobic bacteria or susceptible strains of gram positive bacteria such as Streptococci, Staphylococci and Pneumococci; Upper respiratory infections, Lower respiratory infections, Skin and soft tissue infections, Bone and joint infections, Pelvic infections, Intra-abdominal infections, Septicemia and endocarditis, Dental infections. As alternative therapy when used in combination with quinine or amlodiaquine for the treatment of multi-drug resistant Plasmodium infection.
Dosage & Administration
Dosage of ClindabacTM Capsule
Serious Infections: 150 mg - 300 mg every six hours.
More severe infections: 300 mg - 450 mg every six hours.
To avoid the possibility of oesophageal irritation, ClindabacTM capsules should be taken with
a full glass of water.
Clindamycin should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.
Use in pregnancy & Lactation
Pregnancy Category B: Clindamycin crosses the placenta in humans. After multiple doses, amniotic fluid concentrations were approximately 30% of maternal concentrations. Clindamycin should be used in pregnancy only if clearly needed.
Clindamycin has been reported to appear in breast milk. Therefore, it is not recommended for nursing mothers if not clearly needed.
Use in newborns and infants
When Clindamycin is administered to newborns and infants (birth to 16 years), appropriate monitoring of organ system functions is desirable.
Dose adjustment of Clindamycin is not necessary.